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Purpura: TTP 
Background  
1. Definition  
o Potentially life-threatening hemolytic anemia 
o Characterized by fever, thrombocytopenia, neurologic dysfunction, mild renal 
dysfunction and platelet thrombi in microvasculature 
2. General info  
o TTP clinically similar to Hemolytic Uremic Syndrome  
o TTP characterized by neurologic lesions  
o HUS has renal lesions 
3. Clinical subtypes of TTP  
o Congenital 
o Acquired  
 Acute idiopathic TTP  
 No identifiable precipitant  
 TTP  
 No subsequent relapse  
 Secondary TTP  
 Drugs  
o OCP 
o Ticlopidine 
o Cyclosporine  
o Mitomycin C  
 Post bone marrow transplantation, SLE 
 Malignancy, pregnancy 
 Infection  
o HIV  
o E Coli 0157:H7  
 Intermittent TTP  
o Recurrent episodes at unpredictable intervals  
 
Pathophysiology 
1. Pathology of disease  
o Precise cause unknown 
o Abnormally large multimers of von Willebrand factor found in plasma, usually 
due to decreased activity of von Willebrand factor cleaving protease ADAMTS-
13 
2. Incidence, prevalence  
o 0.04-0.04/1000 
o Pregnant women 0.4/1000 
o Ticlopidine users 0.25-0.7/1000 
3. Risk factors  
o Female gender  
 Women affected 50% more often than men (ratio 3:2) 
o African-American women 
Purpura TTP Page 2 of 4    8.24.09 
o Genetics  
 Familial TTP due to genetic mutation 
4. Morbidity/mortality  
o Untreated: 95% mortality 
o Treated: 10-20% mortality 
 
Diagnostics (SOR:B)  
1. History  
o Weakness 
o Bleeding from the urinary or gastrointestinal tract 
o Pinpoint red rashes, especially around ankles or lower legs 
o Confusion, irritability, seizures 
o Loss of consciousness, coma 
2. Physical examination  
o Fever >100 F° (37.8°C) 
o Petechiae or purpura 
o Pallor when anemia severe 
o Jaundice when hemolysis brisk 
o Tachycardia 
o Confusion or disorientation 
o Delirium 
o Seizures 
o Evidence of mild bleeding from GI or GU tract 
3. Diagnostic testing  
o Laboratory evaluation  
 CBC with low hemoglobin and platelets 
 Peripheral blood smear for schistocytes (hallmark) and thrombocytopenia 
 Elevated reticulocyte count 
 U/A with microscopic urinary sediment evaluation  
 Proteinuria, hematuria, WBCs 
 Mildly elevated BUN, creatinine 
 Elevated total and indirect bilirubin levels 
 Normal PT, fibrinogen, fibrin split products, D-dimer levels 
 Pregnancy test  
 10-25% of TTP patients are pregnant or postpartum 
 HIV  
 TTP may be presenting sign of HIV 
o Other studies (sometimes done to evaluate underlying pathophysiology)  
 Rarely biopsy of affected organ 
 Test for von Willebrand factor cleaving protease activity  
o Imaging studies  
 CT scan of head to assess for intracranial bleeding and infarcts 
4. Diagnostic criteria  
o Classic pentad of thromobocytopenia, fever, microangiopathic hemolytic anemia, 
renal failure and neurologic symptoms 
o Pentad present <50% of patients  
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o Low platelets and a microangiopathic hemolytic anemia  
 TTP must be considered  
 
Differential Diagnosis 
1. DIC  
2. Pre-eclampsia, eclampsia and HELLP syndrome  
3. Idiopathic Thrombocytopenic Purpura  
4. Stroke, hemorrhagic or ischemic  
5. Hemolytic Uremic Syndrome  
6. Sepsis  
7. Malignant hypertension  
8. Autoimmune hemolytic anemia  
 
Therapeutics 
1. Acute treatment (SOR:A) systematic review  
o Plasma exchange (PE) therapy/plasmapheresis 
o Fresh Frozen Plasma (FFP) infusion 30 ml/kg 
o Plasma exchange therapy decreases mortality rate from 90% to 10%  
 7-10 day Tx leads to cure or remission 
o Continue plasma exchange until the platelets count is >150,000 for 2-3 days 
o Typical volumes of plasma infused are 45-77 L of FFP 
2. Further management (SOR:C)  
o None of these have proven superior to PE plus FFP 
o Cryosupernatant  
 Cryoprecipitate-depleted fraction of FFP 
 May be used if PE plus FFP unsuccessful while awaiting splenectomy 
 Dose: 2-4 bags/10 kg  
o Corticosteroids  
 Can be used as adjunct with PE plus FFP in severe cases  
o Splenectomy  
 For refractory cases or relapse 
o Severe refractory cases - immunosuppressive agents – used with PE plus FFP for 
prolonged therapy – no RCTs of effectiveness  
 Vincristine  
 IV immune globulin  
 Rituximab  
 Undergoing large RCT 
 Small study shows benefit with PE and glucocorticoids 
3. Long-term care (SOR:C)  
o Supportive care for end organ damage 
o Red cell transfusion 
o Folic acid  
 1 mg daily 
o Platelet transfusion  
 Contraindicated unless life threatening hemorrhage 
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o Hemodialysis  
 Occasionally for renal failure 
o Phenytoin  
 Prophylactically to minimize seizures 
 100 mg BID-QID  
o Hepatitis B vaccination 
 
Follow Up 
1. During treatment, follow parameters 
2. Hb and HCt - should rise 
3. Platelet count - should rise 
4. LDH, indirect bilirubin - should fall 
5. BUN, creatinine - should fall 
6. Neurologic status - should improve 
7. After treatment periodic follow up with hematologists 
 
Prognosis 
1. Majority of treated patients do well long-term 
2. Relapse rates  
o Vary 12-65% 
o Average 30% at 10 years 
 
Prevention 
1. Patients treated with drugs that have been associated with TTP should not be treated with 
those agents 
2. Familial TTP benefits from scheduled plasma infusion 
3. Splenectomy prevents disease reoccurrence 
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